Cargando…

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

BACKGROUND: Hepatocellular carcinoma (HCC) still represents an unmet medical need. Epigenetic inactivation of tumor suppressor genes like RASSF1A or APC by overexpression of DNA methyltransferases (DNMTs) has been shown to be common in HCC and to be linked to the overall prognosis of patients. Inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zopf, Steffen, Ocker, Matthias, Neureiter, Daniel, Alinger, Beate, Gahr, Susanne, Neurath, Markus F, Di Fazio, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487800/ https://www.ncbi.nlm.nih.gov/pubmed/22943463 http://dx.doi.org/10.1186/1471-2407-12-386

Ejemplares similares

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report
por: Gahr, Susanne, et al.
Publicado: (2012)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
por: Di Fazio, Pietro, et al.
Publicado: (2016)

Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells
por: WACHTER, Julia, et al.
Publicado: (2011)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma
por: Wirries, André, et al.
Publicado: (2018)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation
por: Bekric, Dino, et al.
Publicado: (2022)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
por: Phi, Ji Hoon, et al.
Publicado: (2017)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
por: Ocker, Matthias, et al.
Publicado: (2021)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines
por: Hazama, Yukiko, et al.
Publicado: (2022)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines
por: Pacheco, Mariana Brütt, et al.
Publicado: (2021)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

OR05-06 Histone Deacetylase Inhibitor, Panobinostat, In Combination With A Smac-mimetic For The Treatment Of Ovarian Granulosa Cell Tumours
por: Chu, Simon, et al.
Publicado: (2023)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells
por: Choi, Changhoon, et al.
Publicado: (2021)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma
por: Mayer, Mascha, et al.
Publicado: (2022)

Natural Products Impacting DNA Methyltransferases and Histone Deacetylases
por: Akone, Sergi Herve, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p2qtmhe8vcdqa2prl4cg8pftbq